Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome

Brain and Development

Volumn 32, Issue 5, 2010, Pages 425-427

  Pasini, Augusto ^a   D'Agati, Elisa ^a   Casarelli, Livia ^a   Curatolo, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

22q13.3 deletion syndrome; Risperidone treatment; SHANK3 PROSAP2

Indexed keywords

BENZODIAZEPINE DERIVATIVE; GENE PRODUCT; HALOPERIDOL; PROTEIN PROSAP2; PROTEIN SHANK3; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AGGRESSION; AGITATION; ANEMIA; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CHROMOSOME 22Q13.3 DELETION SYNDROME; CHROMOSOME ANALYSIS; CHROMOSOME DISORDER; COMPARATIVE GENOMIC HYBRIDIZATION; DEVELOPMENTAL DISORDER; EVENING DOSAGE; FEEDING DISORDER; FEMALE; HUMAN; MENTAL DEFICIENCY; MOOD; MORNING DOSAGE; SLEEP DISORDER; VOMITING;

ABNORMALITIES, MULTIPLE; ADOLESCENT; AGGRESSION; ANIMALS; ANTIPSYCHOTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENTAL RETARDATION; PREGNANCY; PSYCHOMOTOR AGITATION; RATS; RISPERIDONE; SYNDROME;

EID: 77951023262     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2009.04.005     Document Type: Article

References (10)

1. Cusmano-Ozog K., Manning M.A., Hoyme H.E. 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. Am J Med Genet C Semin Med Genet 2007, 145C:393-398.
2. Phelan M.C. Deletion 22q13.3 syndrome. Orphanet J Rare Dis 2008, 3:14.
3. Phelan M.C., Rogers R.C., Saul R.A., Stapleton G.A., Sweet K., McDermid H., et al. 22q13 deletion syndrome. Am J Med Genet 2001, 101:91-99.
4. Praphanphoj V., Goodman B.K., Thomas G.H., Raymond G.V. Cryptic subtelomeric translocations in the 22q13 deletion syndrome. J Med Genet 2000, 37(1):58-61.
5. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, and Welfare. Washington DC: Publication ADM; 1976. p. 534-7.
6. Boeckers T.M., Bockmann J., Kreutz M.R., Gundelfinger E.D. ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 2002, 81(5):903-910.
7. Wilson H.L., Wong A.C., Shaw S.R., Tse W.Y., Stapleton G.A., Phelan M.C., et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003, 40:575-584.
8. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005;27(Suppl. A):S16-24.
9. West A.R., Grace A.A. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002, 22:294-304.
10. Choi Y.K., Gardner M.P., Tarazi F.I. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 2008, 19:77-84.